Mike Keenan at Louisiana State University just published his 15th animal study with RS2 resistant starch from high amylose corn. Surprisingly, it was sponsored by Merck and examined the potential synergism between Merck’s drug Januvia® (sitagliptin) and resistant starch. Both impact GLP-1 in the gut, but by different mechanisms. Sitagliptin inhibits the breakdown of GLP-1 Read More …